Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed solid tumor refractory
to conventional therapy or for which no standard therapy exists Measurable or evaluable
disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 2.0
mg/dL (regardless of liver metastases) SGOT/SGPT no greater than 2 times upper limit of
normal Renal: Creatinine no greater than 1.5 mg/dL Calcium no greater than 9.5 mg/dL No
nephrocalcinosis Cardiovascular: No congestive heart failure No angina or ischemia Other:
Ability to swallow or nasogastric or gastrostomy tube present Adequate organ and immune
system function No known hypersensitivity to ILX23-7553 or analogues HIV negative No
active uncontrolled infection No other severe disease or psychiatric disorder that would
preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use
effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered No
concurrent curative antineoplastic drugs Endocrine therapy: Not specified Radiotherapy: At
least 4 weeks since prior radiotherapy and recovered No concurrent curative radiotherapy
Surgery: At least 4 weeks since prior surgery and recovered Other: At least 30 days since
prior investigational agents At least 2 weeks since prior vitamin D, calcium
supplementation, or cholestyramine No concurrent vitamin D, calcium supplementation, or
cholestyramine No concurrent digoxin No concurrent hypercalcemia therapy (i.e.,
biphosphonates or insulin)